Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials

被引：0
|
作者：
Neyns, Bart
Weber, Jeffrey S.
Lebbe, Celeste
Maio, Michele
Harmankaya, Kaan
Hamid, Omid
O'Day, Steven
Chin, Kevin M.
McDowell, Diane Opatt
Cykowski, Lori
McHenry, Brent
Wolchok, Jedd D.
机构：
[1] UZ Brussel, Brussels, Belgium
[2] Comprehens Melanoma Res Ctr, H Lee Moffitt Canc Ctr, Tampa, FL USA
[3] Hop St Louis, Paris, France
[4] Ist Toscano Tumori, Univ Hosp Siena, Siena, Italy
[5] Med Univ Vienna, Div Gen Dermatol, Dept Dermatol, Vienna, Austria
[6] Angeles Clin & Res Inst, Los Angeles, CA USA
[7] Beverly Hills Canc Ctr, Beverly Hills, CA USA
[8] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[9] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[10] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
    Lai-Kwon, Julia
    Jacques, Sarah
    Carlino, Matteo
    Benannoune, Naima
    Robert, Caroline
    Allayous, Clara
    Baroudjian, Barouyr
    Lebbe, Celeste
    Zimmer, Lisa
    Eroglu, Zeynep
    Topcu, Turkan Ozturk
    Dimitriou, Florentia
    Haydon, Andrew
    Lo, Serigne N.
    Menzies, Alexander M.
    Long, Georgina, V
    EUROPEAN JOURNAL OF CANCER, 2023, 186 : 12 - 21
  • [32] Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
    Ascierto, Paolo Antonio
    Del Vecchio, Michele
    Mackiewicz, Andrzej
    Robert, Caroline
    Chiarion-Sileni, Vanna
    Arance, Ana
    Lebbe, Celeste
    Svane, Inge Marie
    McNeil, Catriona
    Rutkowski, Piotr
    Loquai, Carmen
    Mortier, Laurent
    Hamid, Omid
    Bastholt, Lars
    Dreno, Brigitte
    Schadendorf, Dirk
    Garbe, Claus
    Nyakas, Marta
    Grob, Jean-Jacques
    Thomas, Luc
    Liszkay, Gabriella
    Smylie, Michael
    Hoeller, Christoph
    Ferraresi, Virginia
    Grange, Florent
    Gutzmer, Ralf
    Pikiel, Joanna
    Hosein, Fareeda
    Simsek, Burcin
    Maio, Michele
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [33] Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).
    Miller, Wilson H.
    Jamal, Rahima
    Cocolakis, Eftihia
    Thebault, Pamela
    Friedmann, Jennifer Elisabeth
    Kazemi, Shirin
    Dionne, Jeanne
    Cailhier, Jean-Francois
    Lepage, Stephanie
    Belanger, Karl
    Ayoub, Jean-Pierre M.
    Le, H. B.
    Lambert, Caroline
    El Hajjar, Jida
    Van Kempen, Leon
    Spatz, Alan
    Lapointe, Rejean
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [34] A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
    Jamal, Rahima
    Belanger, Karl
    Friedmann, Jennifer Elisabeth
    Ayoub, Jean-Pierre M.
    Cocolakis, Eftihia
    Kazemi, Shirin
    Dionne, Jeanne
    Lambert, Caroline
    Le, H. B.
    Van Kempen, Leon
    Spatz, Alan
    Lapointe, Rejean
    Miller, Wilson H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials
    Lebbe, Celeste
    Weber, Jeffrey S.
    Maio, Michele
    Neyns, Bart
    Harmankaya, Kaan
    Hamid, Omid
    O'Day, Steven
    Chin, Kevin M.
    McDowell, Diane Opatt
    Cykowski, Lori
    McHenry, Brent
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] A phase II single arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classical Kaposi Sarcoma (CKS)
    Zer, A.
    Icht, O.
    Jacobi, O.
    Fenig, E.
    Shamai, S.
    Merimsky, O.
    Shapira, R.
    Bernstine, H.
    Weitzen, R.
    Vornikova, O.
    Ben-Ami, E.
    Bar-Sela, G.
    Stemmer, S. M.
    Lotem, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel)
    Olson, Daniel
    Luke, Jason J.
    Hallmeyer, Sigrun
    Bajaj, Madhuri
    Carll, Timothy
    Krausz, Thomas
    Zha, Yuanyuan
    Karrison, Theodore
    Brockstein, Bruce
    Sondak, Vernon K.
    Eroglu, Zeynep
    Gajewski, Thomas
    Khushalani, Nikhil I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Efficacy of ipilimumab 10 mg/kg in advanced melanoma patients (pts) with good and poor prognostic factors
    Wolchok, J. D.
    de Pril, V.
    Linette, G.
    Waterfield, W.
    Gajewski, T.
    Chiarion-Sileni, V.
    Ibrahim, R.
    Chin, K.
    Hoos, A.
    Hamid, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors
    Schadendorf, D.
    Wolchok, J.
    Neyns, B.
    Lebbe, C.
    Harmankaya, K.
    Verschraegen, C.
    Chin, K.
    de Pril, V.
    Hoos, A.
    Maio, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 579 - 579
  • [40] STUDY OF A COHORT OF PATIENTS WITH METASTATIC MELANOMA TREATED WITH IPILIMUMAB
    Roussel, A.
    Berthe, A.
    Quereux, G.
    Dreno, B. R. I.
    Thomare, P.
    ANNALS OF ONCOLOGY, 2013, 24 : 36 - 36
12345